Efficacy of vaccination against HPV infections to prevent cervical cancer in France: Present assessment and pathways to improve vaccination policies

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Ribassin Majed, Laureen ^a   Lounes, Rachid ^a   Clémençon, Stephan ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER SCREENING; FRANCE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPILLOMAVIRUS INFECTION; SEXUAL TRANSMISSION; UTERINE CERVIX CANCER; VACCINATION; VIRUS TRANSMISSION; AGE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DISEASE TRANSMISSION; FEMALE; HUMAN; IMMUNOLOGY; INCIDENCE; MALE; PREVALENCE; SEX DIFFERENCE; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES;

AGE FACTORS; COMPUTER SIMULATION; FEMALE; FRANCE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MALE; MODELS, BIOLOGICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SEX FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84858027496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032251     Document Type: Article

References (49)

1. Syrjanen K, Hakama M, Saarikoski S, Vayrynen M, Yliskoski M, et al. (1990) Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis 17: 15-19.
2. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S, (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73.
3. Pannier-Stockman C, Segard C, Bennamar S, Gondry J, Boulanger JC, et al. (2008) Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities. J Clin Virol 42: 353-360.
4. Munoz N, (2000) Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19: 1-5.
5. Parkin DM, Pisani P, Ferlay J, (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841.
6. Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, et al. (2003) Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 51: 3-30.
7. Guizard AVTB, (2008) Estimation de l'incidence et de la mortalité par cancer en France de 1980 à 2005. Institut de Veille Sanitaire.
8. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2010) Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102: 325-339.
9. Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H, (2011) HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 29: 3610-3616.
10. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V, (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24: 10-19.
11. Brisson M, Van de Velde N, De Wals P, Boily MC, (2007) The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25: 5399-5408.
12. El Hasnaoui A, Demarteau N, Granados D, Standaert B, Detournay B, (2011) Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France. Int J Public Health.
13. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, et al. (2007) Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 5: 11.
14. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, et al. (2003) A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106: 896-904.
15. Jit M, Choi YH, Edmunds WJ, (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769.
16. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, et al. (2007) Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96: 143-150.
17. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB, (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151: 1158-1171.
18. Suarez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, et al. (2008) Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 26 (Suppl 5): F29-45.
19. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, et al. (2006) Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3: e138.
20. Elbasha EH, Dasbach EJ, Insinga RP, (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13: 28-41.
21. Hughes JP, Garnett GP, Koutsky L, (2002) The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13: 631-639.
22. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM, (2007) Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26: 128-139.
23. Taira AV, Neukermans CP, Sanders GD, (2004) Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10: 1915-1923.
24. Garnett GP, (2005) Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191 (Suppl 1): S97-106.
25. Hethcote HW, (1997) An age-structured model for pertussis transmission. Math Biosci 145: 89-136.
26. Bajos N, Bozon M, Beltzer N, (2008) Enquête sur la sexualité en France: pratiques, genre et santé Paris Découverte.
27. Garnett GP, Anderson RM, (1993) Contact tracing and the estimation of sexual mixing patterns: the epidemiology of gonococcal infections. Sex Transm Dis 20: 181-191.
28. Nielson CM, Harris RB, Flores R, Abrahamsen M, Papenfuss MR, et al. (2009) Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. Cancer Epidemiol Biomarkers Prev 18: 1077-1083.
29. Ralston Howe E, Li Z, McGlennen RC, Hellerstedt WL, Downs LS Jr, (2009) Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol 200: 245 e241-247.
30. Duport N, (2006) Données épidémiologiques sur le cancer du col de l'utérus/état des connaissances Saint Maurice InVS.
31. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL, (2006) Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 (Suppl 3): S3/26-34.
32. Peto J, Gilham C, Deacon J, Taylor C, Evans C, et al. (2004) Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91: 942-953.
33. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, et al. (2008) Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 56: 159-175.
34. Duport N, (2008) Données épidémiologiques sur le cancer du col de l'utérus/état des connaissances Saint Maurice INVS.
35. Jin XW, Sikon A, Yen-Lieberman B, (2011) Cervical cancer screening: Less testing, smarter testing. Cleve Clin J Med 78: 737-747.
36. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, et al. (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 105: 28-37.
37. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
38. Rambout L, Hopkins L, Hutton B, Fergusson D, (2007) Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177: 469-479.
39. UK Department of Health website HPV Vaccination Programme: Provisional data, as submitted by PCTs, for First and Second dose vaccine uptake, for the month ending 28 February 2010. Available: http://www.dh.gov.uk/prod_consum_h/groups/dh_digitalassets/documents/digitalasset/dh_115153.pdf. Accessed 2011 Aug 4.
40. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, et al. (2008) Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 32: 457-461.
41. Denis FL-BD, (2006) Mass vaccination against hepatitis B: the French example. Curr Top Microbiol Immunol 304: 115-129.
42. ECCA European Cervical Cancer Association website HPV vaccination accross Europe. Available: http://www.ecca.info/fr/ecca-publications.html. Accessed 2011 Jun 5.
43. "Haut Conseil Santé Publique" website AVIS DU COMITE TECHNIQUE DES VACCINATIONS et du CONSEIL SUPERIEUR D'HYGIENE PUBLIQUE DE FRANCE SECTION DES MALADIES TRANSMISSIBLES Relatif à la vaccination contre les papillomavirus humains 6, 11, 16 et 18 (séances du 9 mars 2007). Available: http://www.hcsp.fr/docspdf/cshpf/a_mt_090307_papillomavirus.pdf. Accessed 2011 Dec 27.
44. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC, (2011) Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 204: 372-376.
45. Castle PE, Scarinci I, (2009) Should HPV vaccine be given to men? BMJ 339: b4127.
46. Elbasha EH, Dasbach EJ, (2010) Impact of vaccinating boys and men against HPV in the United States. Vaccine 28: 6858-6867.
47. Foresta C, Ferlin A, Garolla A, (2009) HPV vaccination. What about male specific HPV related diseases? BMJ 339: b4514.
48. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
49. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.